Document:

tronbiontechmymutlmtrans

Seite 1/3 Bankverbindung: Mainzer Volksbank eG, IBAN: [***], BIC: [***] Amtsgericht Mainz: HRB 43191 - USt.-Id.Nr.: DE 269156552 [***] TRON gGmbH, Freiligrathstraße 12, D-55131 Mainz TRON gGmbH  FreiligrathstraBe 12  D - 55131 Mainz  [***] [***] [***] [***] [***] [***] [***] 05.05.2021 BioNTech SE An der Goldgrube 12 55131 Mainz Transfer of Source Code for MyMUT® Software Versions [***] on May 5th 2021  TRON gGmbH hereby transfers the full source code of the MyMUT® software versions [***] under the URL  [***], encrypted zip archive (the “SOURCE CODE”); the key will be sent separately as a printout). With regard  to the use of the data and the software by BioNTech SE, TRON recognizes that the software will be used for  the so-called IVAC project. Since the IVAC Supplementary Agreement dated January 1st 2015 between TRON and BioNTech expired on  December 31st 2019 and no other related agreement between BioNTech SE and TRON gGmbH has been  concluded so far, TRON hereby transfers these data (including inventions, rights to patent applications /  patents and so-called trade secrets) subject to the rights of use to which TRON, TRON AFFILIATED  COMPANIES and the respective cooperation partners are entitled in the IVAC Supplementary Agreement with  the proviso that Sec. 6.4.1. of the Framework Collaboration Agreement ( "WP5") between BioNTech SE and  TRON gGmbH is applied as amended in Schedule 1, which amendment shall be effective solely for the  purpose of this letter and the exploitation of the SOURCE CODE including any so called trade secret  inventions contained in the SOURCE CODE. All other terms of the IVAC Supplementary Agreement shall  remain unaffected. The parties further agree, via separate amendment, to extend the term of the IVAC  Supplementary Agreement to Dec. 31st 2023.  BioNTech SE accepts this transfer under this letter agreement and recognizes the fulfillment of the  obligations by TRON according to the IVAC Supplementary Agreement with regard to the above data. Mainz, ......................................................... Mainz, ........................................................... /s/ Michael Föhlings................................................................../s/ Dr. Andrée Rothermel       /s/ Sierk Poetting .................................................................. Michael Föhlings        Dr. Andrée Rothermel Sierk Poetting 1 oocuSigned by:  L~  lnDocuSigned by:  ~~~B~~J,  [ DocuSigned by:  > ,,,;---::,  E78E248002F342F ...  • TRON - Translationale Onkolog ie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnUtzige GmbH  TRON    -  Tr nsl ti l  Onkol i  an der  Uni rsität di i  der Johan   t r - ä  ainz ge ei ützi     THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN  EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE  COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 4.55 

 

Seite 2/3 Bankverbindung: Mainzer Volksbank eG, IBAN: [***], BIC: [***] Amtsgericht Mainz: HRB 43191 - USt.-Id.Nr.: DE 269156552 [***] Managing Director     Managing Director CFO, Managing Director BioNTech Schedule 1 Amendment to Sec. 6.4.1. of the Framework Collaboration Agreement ( "WP5") This Amendment is agreed by the PARTIES for the sole purpose of regulating the remuneration payable  by the relevant BIONTECH PARTY to TRON for the exploitation of a TRADE SECRET INVENTION  to the extent any such TRADE SECRET INVENTION is part of the source code of the MyMUT®  software versions L and M under the URL [***] encrypted zip archive (the “SOURCE CODE”). For  this purpose only, Sec. 6.4.1 of the Framework Collaboration Agreement (“WP5”) will read as follows: “For the WP5 CONTRACTUAL PRODUCTS sold by it or its licensees (or sublicensees) to THIRD  PARTIES which fall within the scope of protection of a VALID CLAIM of a WP5 PROJECT PATENT  or a TRADE SECRET INVENTION, the BIONTECH PARTY shall pay TRON remuneration to the  amount of (i) [***] percent ([***]) of the WP5 CONTRACTUAL PRODUCT's NET SELLING PRICE up to an annual aggregate worldwide NET SELLING PRICE per WP5 CONTRACTUAL PRODUCT of [***]) euro (€[***]); and (ii) [***] percent ([***]) of the WP5 CONTRACTUAL PRODUCT's NET SELLING PRICE if the annual aggregate worldwide NET SELLING PRICE per WP5 CONTRACTUAL PRODUCT exceeds [***] euro (€[***]). The aforementioned remuneration under this clause 6.4.1 shall be paid on a country-by-country basis for  so long as the relevant WP5 CONTRACTUAL PRODUCT is covered by a VALID CLAIM of a WP5  PROJECT PATENT in the country of sale.  If a WP5 CONTRACTUAL PRODUCT falls within the scope of a TRADE SECRET INVENTION, it  is the mutual expectation of the PARTIES that the exploitation of such TRADE SECRET INVENTION  will be coherent and jointly together with the exploitation of one or more WP5 PROJECT PATENTS. Based on that understanding, the royalty pursuant to this clause 6.4.1 for the use of a TRADE SECRET  INVENTION shall only be payable (x) if the relevant WP5 CONTRACTUAL PRODUCT also falls  within the scope of protection of a VALID CLAIM of a WP5 PROJECT PATENT or, (y) in the event  that the BIONTECH PARTY should exploit a TRADE SECRET INVENTION by entering into an  agreement with a THIRD PARTY, if the relevant WP5 CONTRACTUAL PRODUCT also falls within  the scope of protection of a VALID CLAIM of a patent ( co )owned by such THIRD PARTY ("THIRD PARTY PATENT").  The royalty is payable, on a WP5 CONTRACTUAL PRODUCT-by- WP5 CONTRACTUAL  PRODUCT basis, only once per WP5 CONTRACTUAL PRODUCT, even if a WP5 CONTRACTUAL PRODUCT falls within the scope of protection of several WP5 PROJECT PATENTS and/or TRADE  SECRET INVENTIONS. • TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnUtzige GmbH  TRON    -  Tr nsl ti l  Onkol i   an der  Uni rsität di i  der Johan   t r - ä  ainz ge ei ützi     

 

Seite 3/3 Bankverbindung: Mainzer Volksbank eG, IBAN: [***], BIC: [***] Amtsgericht Mainz: HRB 43191 - USt.-Id.Nr.: [***]. [***]. For the avoidance of doubt, the sentence in Sec. 6.4.1. of the Framework Collaboration Agreement  "WP5") starting “If such exploitation is undertaken.....” shall be deleted in its entirety.” For all other purposes the original version of Sec. 6.4.1 shall remain unchanged, in full effect and shall  not be affected by the aforementioned amendment.    • TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnUtzige GmbH  TRON    -  Tr nsl ti l  Onkol i   an der  Uni rsität di i  der Johan   t r - ä  ainz ge ei ützigenmabamendmentno6collab

[***] AMENDMENT No 6  to  the License and Collaboration Agreement of 19th May 2015  by and between  BioNTech SE  and  GenmabA/S  THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN  EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE  COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 4.62 

 

[***]  This Amendment No 6 is made and entered into as of June 01, 2021 ("Amendment No 6 Effective  Date") by and between BioNTech SE, a German corporation having its principal office at An der  Goldgrube 12, 55131 Mainz, Germany ("Biontech") and Genmab A/S, CVR no. 21023884, a Danish  corporation having its principal office at Kalvebod Brygge 43, DK-1560 Copenhagen V, Denmark,  on the other side ("Genmab").  (for the purposes of this Amendment No 6, Biontech and Genmab each a "Party" and together the  "Parties").  PREAMBLE  WHEREAS, Biontech and Genmab are parties to a certain License and Collaboration Agreement of  19th May 2015 as amended by:  1) the Amendment No 1 dated May 18, 2017, Amendment No 2 dated August 4, 2017, Amendment No. 3 dated May 18, 2018, Amendment No. 4 dated November 25, 2019, Amendment No 5 dated May 08, 2020, 2) the Side Letter dated January 8, 2016, a Side Letter No 2 dated May 13, 2016 (as amended by the Amendment No 1 to Side Letter No 2 dated May 19, 2017 as well as Amendment No 2 to Side Letter No 2 dated May 18, 2018 as well as Amendment No. 3 to the Side Letter No. 2 dated 18 August 2020), a Side Letter No 3 dated September 25, 2017, a Side Letter No 4 dated October 6, 2020, as well as 3) a Letter Agreement dated January 29, 2020, a Letter Agreement dated February 04, 2020 (as amended by Amendment of Letter Agreement dated June 29, 2020) and a Letter Agreement dated November 11, 2020 with an effective date of September 10, 2020 (jointly referred to as the "Agreement");  WHEREAS, Biontech and Genmab wish to adjust the FTE rate;  NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements  herein contained, and for good and valuable consideration the receipt and sufficiency of which are  hereby acknowledged, the Parties, intending to be legally bound, hereby agree to amend the  Agreement as follows:  1. DEFINITIONS 1.1. Except as otherwise defined herein, the words and phrases in the Agreement shall have the same meaning in this Amendment No 6.  1.2. "Amendment No 6" shall mean this Amendment No 6 to the Agreement.  1.3. "Amendment No 6 Effective Date" shall have the meaning set forth in the first  paragraph on the second page of this Amendment No 6.  

 

[***]  1.4. References to "Sections" refer to sections of the Agreement and references to "clauses"  refer to clauses of this Amendment No 6.  2. AGREED AMENDMENTS 2.1. The Parties agree to amend the Agreement as follows: 2.1.1. Section 7 .2 of the Agreement is deleted in its entirety and replaced by the below new Section 7.2 with retroactive effect from the Effective Date:  "7.2 FTE Rate. The Parties agree that the mutual annual rate per FTE of either  Party who performs research, Development, consultation or support work  under any Research or Development Plan is as follows:  a. Up until and including 18th May 2018: [***]. b. From and including 19th May 2018 up until and including 30 March  2019: [***]. c. From and including 1 April 2019 up until and including 30 March 2020:  [***]. d. From and including 1 April 2020 up until and including 30 June 2020:  [***]. e. From and including 1 July 2020 up until and including 31 December  2020: [***]. f From and including 1 January 2021 up until and including 31 December  2021: [***].  g. From and including 1 January 2022 and onwards: [***] [***] which shall be adjusted on an annual basis in accordance with the  following sentence. [***]. 

 

[***]  3. MISCELLANEOUS 3.1. Save as set forth in this Amendment No 6, all other terms and conditions of the Agreement shall remain in full force and effect.  3.2. This Amendment No 6 shall form an integral part of the Agreement and shall be  regarded as incorporated into the Agreement in every respect as from the relevant dates  stated above.  3.3. The Agreement and this Amendment No 6 constitute the entire agreement between the  Parties and supersedes and extinguishes all previous agreements, promises, assurances,  warranties, representations and understandings between them, whether written or oral,  relating to its subject matter. In the event of any conflict, ambiguity or inconsistency  between the provisions of this Amendment No 6 and the Agreement, the provisions of  this Amendment No 6 shall prevail. Except as specifically modified by this Amendment  No 6, the remainder of the terms of the Agreement shall remain in full force and effect,  unamended.  3.4. This Amendment No 6 and any dispute or claim (including non-contractual disputes or  claims) arising out of or in connection with it or its subject matter or formation shall be  governed by and construed in accordance with the laws of England and Wales without  reference to its conflict of laws provisions.  3.5. This Amendment No 6 may be signed in any number of counterparts with the same  effect as if the signatures to each counterpart were upon a single instrument, and all  such counterparts together shall be deemed an original of the Amendment No 6.  3.6. The Parties agree that this Agreement can be signed using a DocuSign® electronic  signature. Such electronic signature is the legally binding equivalent to a Party's  handwritten signature and it has the same validity, enforceability and meaning as a  handwritten signature and the Parties hereby waive any objection to the contrary.  Signature  

 

[***]  IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Amendment No 6 as of the Amendment No 6 Effective Date. BioNTech SE: GenmabA/S  Date: 01.06.2021 03.06.2021  Date: Signature: Print name: Managing Director Title: Sean Marett Print name: Managing Director  Title: 09-Jun-2021 Anthony Mancini EVP & COO  [***] Sierk Poetting Signature [***] [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]